Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii.

摘要: Abstract Objective To determine the effects on mother to child transmission of timing and type prenatal treatment, taking into account gestational age at maternal seroconversion. Design Prospective cohort study. Setting European centres offering screening for toxoplasmosis. Population Children born a pregnant women with toxoplasma infection. Methods We determined interval between seroconversion start treatment (treatment delay), Main outcome measure Congenital infection status confirmed by IgG results one year postnatal age. Results Of 1208 analysed, 72% were first prescribed spiramycin, 19% pyrimethamine–sulphonamide 9% (mostly infected during last trimester) untreated. The odds ratios all treated after delay four seven weeks was 0.77 (95% CI 0.34–1.69), eight or more 1.33 (0.56–2.89) compared less than weeks. ratio per week 1.01 (0.93–1.08). There no evidence that risk differed in versus spiramycin: 1.10 (0.63–1.91) untreated women: 0.57 (0.27–1.17). Conclusion unable demonstrate beneficial effect but we could not exclude clinically important effect. Randomised controlled trials are required transmission.